

30 March 2021

Tender results

PHARMAC has resolved to award tenders for Principal Supply Status for some products included in the 2020/21 Invitation to Tender, dated 2 November 2020 and has resolved to award tenders for Sole Subsidised Supply Status and Hospital Supply Status for some products included in the 2018/19 Invitation to Tender, dated 1 November 2018.

Some of the pharmaceuticals that will be delisted when the period of Principal Supply Status, Sole Subsidised Supply Status, Hospital Supply Status (as relevant) commences may be subject to existing listing contracts with PHARMAC. Suppliers of pharmaceuticals that are subject to such contracts should continue to supply their pharmaceuticals under those contracts. PHARMAC will continue to subsidise those pharmaceuticals accordingly until such time as those pharmaceuticals are delisted.

Notification of Product Changes (NOPC) forms

Please note that for any changes (price change, pack size change, new listing etc.) to be effective in the Pharmaceutical Schedule (including Section H), suppliers are required to submit a Notification of Product Changes (NOPC) form to PHARMAC, the Pharmacy Guild and the NZULM by:

- **For new listings**, by 4pm on the 12th of April 2021 or the 5th of the month prior to listing, whichever is earlier
- **For price changes**, by 4pm on the 12th of the month prior to the date of subsidy change

PHARMAC cannot list a product (and pharmacies cannot claim) without this information. More information about this process, and a copy of the NOPC form can be found on our website –<https://pharmac.govt.nz/medicine-funding-and-supply/make-an-application/pharmconnect-make-a-medicine-funding-application/process-for-notification-of-product-changes/>

Suppliers are required to ensure that a Pharmacode has been obtained from the Pharmacy Guild of New Zealand (<http://www.pgnz.org.nz/about-us-1/pharmacode>) and that a CTPP code has been obtained from the New Zealand Universal List of Medicines (<http://www.nzulm.org.nz/sponsors>). Pharmacodes and CTPP codes must be provided to PHARMAC by the 5th of the month prior to

the date of listing, or 10 business days following the market notification date (whichever is earliest). PHARMAC cannot list a product (and pharmacies cannot claim) without the correct Pharmacode.

2018/19 Tender – Sole Subsidised Supply Status or Hospital Supply Status applies until 30 June 2022

Community pharmaceutical tenders – Section B of the Pharmaceutical Schedule

1. *Tenders awarded to currently listed pharmaceuticals where no other brand is listed.*

The decisions were as follows:

Chemical name	Presentation; Pack size and type	Current pack price	New pack price	Sole supply brand (Supplier)	Date of listing	Sole Subsidised Supply date
Levonorgestrel	Tab 1.5 mg; 1 tab pack	\$4.95	\$4.95	Postinor-1 (Bayer New Zealand Ltd)	1 October 2021	1 March 2022

Hospital pharmaceutical tenders – Section H of the Pharmaceutical Schedule

2. *Tenders awarded to currently listed pharmaceuticals where no other brand is listed.*

The decisions were as follows:

Chemical name	Presentation; Pack size and type	Current pack price	New pack price	Sole supply brand (Supplier)	DV limit	Date of listing	Hospital Supply Status date
Levonorgestrel	Tab 1.5 mg; 1 tab pack	\$4.95	\$4.95	Postinor-1 (Bayer New Zealand Ltd)	1%	1 October 2021	1 March 2022

2020/21 Tender – Principal Supply Status applies until 30 June 2024

Community pharmaceutical tenders – Section B of the Pharmaceutical Schedule

3. *Tenders awarded to currently listed pharmaceuticals where no other brand is listed.*

The decisions were as follows:

Chemical name	Presentation; Pack size and type	Current pack price	New pack price	Principal Supply brand (Supplier)	Date of subsidy change	Principal Supply date
Aprepitant ¹	Cap 2 x 80 mg and 1 x 125 mg; 3 capsule OP blister pack	\$84.00	\$30.00	Emend Tri-pack (Merck Sharp & Dohme (New Zealand) Limited)	1 July 2021	1 December 2021
Brimonidine tartrate ¹	Eye drops 0.2%; 5 ml OP dropper bottle	\$12.25	\$4.29	Arrow – Brimonidine (Teva Pharma New Zealand Ltd)	1 August 2021	1 January 2022
Disulfiram ¹	Tab 200 mg; 100 tablet blister pack	\$250.00	\$236.40	Antabuse (Teva Pharma New Zealand Ltd)	1 June 2021	1 November 2021

¹This product will be supplied at the Price from the 1st day of the month prior to the listing date, as per Schedule 5, clause 3.1 (b)(II) of the 2020/21 Invitation To Tender.

4. *Tenders awarded to pharmaceuticals where at least one other brand is listed.*

The decisions were as follows:

Chemical name	Presentation; Pack size and type	Current pack price	New pack price	Principal Supply brand (Supplier)	Date of listing	Principal Supply Status date	Brand (Supplier) affected by delisting
Ibuprofen	Tab long-acting 800 mg; 30 tablet blister pack	\$5.99	\$3.05	Brufen SR (Mylan New Zealand Ltd)	1 August 2021	1 January 2022	Ibuprofen SR BNM (Boucher and Muir (NZ) Limited)

Hospital pharmaceutical tenders – Section H of the Pharmaceutical Schedule.

5. *Tenders awarded to currently listed pharmaceuticals where no other brand is listed.*

The decisions were as follows:

Chemical name	Presentation; Pack size and type	Current pack price	New pack price	Principal Supply brand (Supplier)	DV limit	Date of subsidy change	Principal Supply date
Aprepitant ²	Cap 2 x 80 mg and 1 x 125 mg; 3 blister pack	\$84.00	\$30.00	Emend Tri-pack (Merck Sharp & Dohme (New Zealand) Limited)	5%	1 July 2021	1 December 2021
Brimonidine tartrate ²	Eye drops 0.2%, 5 ml dropper bottle	\$12.25	\$4.29	Arrow – Brimonidine (Teva Pharma New Zealand Ltd)	5%	1 August 2021	1 January 2022
Disulfiram ²	Tab 200 mg; 100 tablet, blister pack	\$250.00	\$236.40	Antabuse (Teva Pharma New Zealand Ltd)	5%	1 June 2021	1 November 2021

²This product will be supplied at the Price from the 1st day of the month prior to the listing date, as per Schedule 6, clause 3.1 (b)(II) of the 2020/21 Invitation To Tender.

6. *Tenders awarded to pharmaceuticals where at least one other brand is listed.*

The decisions were as follows:

Chemical name	Presentation; Pack size and type	Current pack price	New pack price	Principal Supply brand (Supplier)	DV limit	Date of listing	Principal Supply Status date	Brand (Supplier) affected by delisting
Ibuprofen	Tab long-acting 800 mg; 30 tablet blister pack	\$5.99	\$3.05	Brufen SR (Mylan New Zealand Ltd)	5%	1 August 2021	1 January 2022	Ibuprofen SR BNM (Boucher and Muir (NZ) Limited)

Tender declines - Products where no tender is to be awarded for Principal Supply Status

PHARMAC has resolved not to award tenders for Principal Supply Status for the following products listed in the 2020/21 Invitation to Tender, dated 2 November 2020

2020/21 Invitation to Tender

Chemical name	Line item
Amphotericin B	Liposomal inj 50 mg
Aprepitant (widened access)	Cap 2 x 80 mg and 1 x 125 mg
Benzbromarone	Tab 25 - 100 mg
Cidofovir	Inj 75 mg per ml, 5 ml
Ciprofloxacin	Inj 2 mg per ml, 100 ml
Diltiazem Hydrochloride	Inj 5 mg per ml, 5 ml vial
Diltiazem hydrochloride	Tab 30 mg
Diltiazem hydrochloride	Tab 60 mg
Doxorubicin	Inj 10 mg
Doxorubicin	Inj 100 mg
Doxorubicin	Inj 50 mg
Gentamicin sulphate	Inj 10 mg per ml, 1 - 2 ml
Gentamicin Sulphate	Inj 40 mg per ml, 2 ml
Glyceryl trinitrate	Tab sublingual 600 mcg
Haloperidol decanoate	Inj 100 mg per ml, 1 ml
Haloperidol decanoate	Inj 50 mg per ml, 1 ml
Hydrocortisone	Oral liq
Hydrocortisone	Tab 1 mg
Hydrocortisone	Tab 20 mg
Hydrocortisone	Tab 4 mg

Chemical name	Line item
Hydrocortisone	Tab 5 mg
Loperamide hydrochloride [split market]	Tab 2 mg
Metformin Hydrochloride	Cap/tab sustained-release 1 g
Metformin Hydrochloride	Cap/tab sustained-release 500 mg
Methadone hydrochloride	Inj 10 mg per ml, 1 ml
Metronidazole	Gel 0.75%
Morphine Hydrochloride	Oral liq 1 mg per ml
Morphine Hydrochloride	Oral liq 10 mg per ml
Morphine Hydrochloride	Oral liq 2 mg per ml
Morphine Hydrochloride	Oral liq 5 mg per ml
Nitrazepam	Tab 5 mg
Norfloxacin	Tab 400 mg
Pizotifen	Tab 500 mcg
Potassium citrate	Tab
Tenecteplase	Inj 50 mg
Terlipressin	Inj 0.2 mg per ml, 10 ml
Ziprasidone	Cap 20 mg
Ziprasidone	Cap 40 mg
Ziprasidone	Cap 60 mg

For products included in the 2018/19, 2019/20 or 2020/21 Invitation to Tender where no announcement has yet been made, either a decision is still pending or is provisional, subject to the product gaining market approval and being available to supply, and subject to PHARMAC Board (or its delegate) approval. We will keep you informed of any updates regarding such tender products as decisions are made.

If you have any queries regarding this notification, please contact PHARMAC on 0800 66 00 50.